Yolanda Mageto, MD
Pulmonary Disease · Dallas, TXNPI 1497816862
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $180,895 of the $239,378 with a category attached, or 75.6%. Boehringer Ingelheim accounts for 65.3% of it on its own, with 20 other manufacturers making up the rest. Among pulmonary disease clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 291 payments — averaging $822.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$156K
- ANI Pharmaceuticals, Inc.$30K
- Genentech USA, Inc.$28K
- United Therapeutics Corporation$20K
- E.r. Squibb & Sons, L.L.C.$2K
- CSL Behring$2K
- plus $1K from 15 others
Across 279 payments — averaging $4011.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$455K
- AstraZeneca$213K
- E.r. Squibb & Sons, L.L.C.$169K
- CSL Behring$97K
- United Therapeutics Corporation$77K
- Bristol Myers Squibb$57K
- plus $53K from 4 others
What the payments were for
- Consulting fees$25,64311%
- Speaking & faculty fees$180,89576%
- Travel & lodging$25,15611%
- Food & beverage$7,6843%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 133 | $156,286 |
| ANI Pharmaceuticals, Inc. | 39 | $30,081 |
| Genentech USA, Inc. | 26 | $27,908 |
| United Therapeutics Corporation | 25 | $20,126 |
| E.r. Squibb & Sons, L.L.C. | 2 | $1,959 |
| CSL Behring | 8 | $1,816 |
| GSK | 14 | $242 |
| Insmed, Inc. | 9 | $220 |
| AstraZeneca | 9 | $136 |
| Sanofi | 4 | $134 |
| Grifols USA, LLC | 4 | $95 |
| Vifor Pharma, Inc. | 3 | $85 |
| Actelion Pharmaceuticals US, Inc. | 4 | $69 |
| Itamar Medical Inc | 2 | $57 |
| Mallinckrodt Hospital Products Inc. | 2 | $40 |
| Philips North America LLC | 2 | $28 |
| Regeneron Healthcare Solutions, Inc. | 1 | $26 |
| Verona Pharma, Inc. | 1 | $23 |
| Merck | 1 | $18 |
| Gilead | 1 | $17 |
| AbbVie | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PURIFIED CORTROPHIN GEL$29,194
- Esbriet$27,594
- OFEV$16,893
- TYVASO$13,969
- SPIRIVA RESPIMAT$3,600
- REMODULIN$152
How this compares
$239,378 in reported general payments places this provider in the 95th percentile of 904 pulmonary disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 112 | $1,470,585 |
| Tyvaso DpiTreprostinil | 36 | $867,014 |
| Pirfenidone | 88 | $294,531 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 188 | $159,988 |
| RemicadeInfliximab | 11 | $80,325 |
| Breo ElliptaFluticasone/Vilanterol | 67 | $34,802 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 28 | $19,112 |
| Mycophenolate Mofetil | 126 | $14,920 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 17 | $10,638 |
| Mycophenolic AcidMycophenolate Sodium | 70 | $9,979 |
| EliquisApixaban | 17 | $9,894 |
| Advair HfaFluticasone Propion/Salmeterol | 19 | $8,563 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 38 | $7,020 |
| SymbicortBudesonide/Formoterol Fumarate | 27 | $6,538 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 97 | $3,135 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat | $156,286 | $1,481,223129 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $242 | $213,903283 claims |
| AstraZenecaSymbicort | $136 | $6,53827 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 904 pulmonary disease providers in Texas.
Other pulmonary disease in Dallas
- Mark MillardDallas$192K
- Raksha JainDallas$153K
- Sonja BartolomeDallas$75K
- Kelly ChinDallas$72K
- Fernando TorresDallas$61K
- Antonio AnzuetoSan Antonio$1.8M
- Diego Maselli CaceresSan Antonio$1.5M
- Nicola HananiaHouston$1.3M
- Juan IribarrenBeaumont$915K
- William CalhounGalveston$568K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.